SKK
ABUS icon

Shepherd Kaplan Krochuk’s Arbutus Biopharma ABUS Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-17,418
Closed -$139K – 579
2013
Q4 		$139K Hold
17,418
– – 0.02% 468
2013
Q3 		$121K Hold
17,418
– – 0.02% 499
2013
Q2 		$82K Buy
+17,418
New +$82.5K 0.02% 536

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
SCM
Sigma Capital Management Stamford, Connecticut $1.95B AUM 42.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shepherd Kaplan Krochuk's ABUS Position: Q1 2014 in Review

Shepherd Kaplan Krochuk sold out of Arbutus Biopharma (ABUS) in Q1 2014, closing a stake of 17,418 shares — an estimated $139K sold.

Shepherd Kaplan Krochuk first reported a position in ABUS in Q2 2013 and held it in 3 quarters. The position peaked at $139K in Q4 2013. 50 funds tracked by Wall St. Rank hold ABUS as of Q1 2014.

  • Shepherd Kaplan Krochuk reported no remaining Arbutus Biopharma position as of Q1 2014 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 17,418 Arbutus Biopharma shares in Q1 2014, an estimated $139K.
  • Shepherd Kaplan Krochuk first reported a position in Arbutus Biopharma in Q2 2013 and held it in 3 quarters.
  • Shepherd Kaplan Krochuk's Arbutus Biopharma position peaked at $139K in Q4 2013.
  • 50 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2014.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2014, filed 15 May 2014.